MiMedx Responds To Deceptive Short Seller Reports

Thursday, September 21, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

MARIETTA, Ga., Sept. 20, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing

and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, responds to deceptive short seller articles published earlier today.  

Earlier

today, two short seller articles, one by Viceroy Research and the other by Aurelius Value, were published on MiMedx. Parker H. "Pete" Petit, CEO, said, "The articles include several items that have virtually no basis in fact, are littered with innuendo and contain many statements that are simply not correct. This has all the markings of a concerted short seller attack by numerous entities attempting to short our stock and profit from fictitious information and innuendos. We believe that Viceroy Research and Aurelius Value are relying on misinformation from former MiMedx employees terminated for cause. Unfortunately, neither organization appears to have done adequate due diligence and fact-finding before publishing their so-called 'research reports.' We have scheduled a shareholder call tomorrow, Thursday, September 21st, at 10:30 am Eastern Time to discuss various topics on the Company's extremely positive performance and trajectory for future growth. We will also address this orchestrated short seller activity and the remedies the Company is seeking to have this unlawful practice of pushing fabricated information to shareholders in concert with coordinated short selling activity cease."

In the meantime, the Company encourages all shareholders to review the detailed and factual press releases the Company has issued and other reports on the Company's website www.mimedx.com.

About MiMedxMiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary StatementThis press release includes forward-looking statements, including statements regarding the focus of the SEC subpoena, that the subpoena matter may be cleared up quickly, the Company's belief that Viceroy Research and Aurelius Value are relying on misinformation from former MiMedx employees terminated for cause and that inadequate due diligence was performed before publishing reports on the Company,  and the Company's belief that there has been a concerted short seller attack by entities attempting to short the Company's stock.  These statements also may be identified by words such as "believe," "except," "may," "plan," "potential," "will" and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements.  Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that different or additional facts may be discovered that change conclusions. For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

View original content:http://www.prnewswire.com/news-releases/mimedx-responds-to-deceptive-short-seller-reports-300523150.html

SOURCE MiMedx Group, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook